NP Medical News about Diabetic Neuropathies Cannabis Sativex

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A Randomised Placebo Controlled Double Blind Clinical Trial of Cannabis Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a Major Confounding Factor
Diabetes Care, 10/09/09

Selvarajah D et al. – This first ever, trial assessing the efficacy of cannabis has shown it to be no more efficacious than placebo in painful–DPN. Depression was a major confounder and may have important implications for future painful–DPN trials.

Methods

In this randomized controlled trial, 30 subjects with painful–DPN received daily Sativex or placebo.
Primary outcome measure was change in mean daily pain scores and secondary outcome measures included quality of life assessments.

Results

There was significant improvement in pain scores in both groups but mean change between groups was not significant.
There were no significant differences in secondary outcome measures.
Patients with depression had significantly greater baseline pain scores that improved regardless of intervention.

<< Previous
New USP Standard for Heparin Decreases Unit Dose Potency,...

Next >>
Occupational injury in the United Arab Emirates: epidemiology and...